Silexion submits Phase 2/3 trial application for SIL204 in locally advanced pancreatic cancer

Silexion Therapeutics Corp

Submitted Phase 2/3 clinical trial application in Israel for SIL204, a siRNA therapy for locally advanced pancreatic cancer (LAPC).
Phase 2/3 trial initiation planned for Q2 2026; follow-on regulatory filings in Germany/EU in Q1 2026.
Preclinical data demonstrated up to 99.7% cancer cell inhibition across multiple KRAS mutations.
Two completed species toxicology studies confirmed no systemic organ toxicity; positive German regulatory feedback received.
Collaborating with Sheba Medical Center (top-10 global hospital) for Israeli trial; U.S. expansion after safety run-in.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.